XENOTHERA
5.1.2023 18:01:38 CET | Business Wire | Press release
In the context of a major resurgence of the COVID epidemic, the French biotech XENOTHERA announces recent data in favor of the strong interest of its glyco-humanized polyclonal antibody (GH-pAb) XAV-19 to treat patients in the initial viral phase of the disease.
Several neutralization assays carried out by XENOTHERA have supplemented data already published (Vanhove et al. 2020, 2021, 2022). XAV-19 exhibits a strong neutralization activity against all omicron variants, including BQ.1.1, the main variant of SARS-CoV-2 in circulation to date. In the meantime, all monoclonal antibodies today marketed lose their activity against this variant. The neutralizing concentration of XAV-19 (IC50) is identical to that measured for all other variants of SARS-CoV-2.
XAV-19 is in clinic since 2020, with more than 700 patients having participated in trials in France, Bulgaria, Spain, Romania, Greece, and Turkey. The biotech has recently released the first results of its phase II/III clinical trial EUROXAV, suspended due to a low enrollment. Preliminary analysis show that XAV-19 tends to improve the recovery rate and to lower the aggravation risk for moderate patients at WHO score 2, within 6 days after symptoms onset. No safety issue has been raised during the trials.
PK data from patients treated with XAV-19 show a trough level ten times higher than the IC50 (Gaborit et al. 2021). In total, one single injection of XAV-19 is likely to neutralize the BQ.1.1 virus or any other variant during the viral phase of the disease.
Considering the current pandemic situation where there is no remaining therapeutic solution for immuno-compromised patients, for whom the administration of anti-COVID antibodies is essential, XAV-19 from XENOTHERA seems to be one of the most promising candidates to address this medical need.
In parallel, the biotech goes on with 3 products in clinic today and an attractive oncology portfolio.
"Today we reiterate our commitment for serving patients and the medical community. While COVID persists as a life-threatening concern, XAV-19 should be considered, in view of its safety and efficacy, particularly on variants, as a viable therapeutic solution for immunocompromised individuals who do not produce their own antibodies. In view of the benefit/risk ratio, we are more than ever ready to move quickly to make XAV-19 available to physicians and patients. In the meantime, we develop further our whole portfolio, particularly in oncology where unmet medical needs are huge also." comments Odile Duvaux, CEO and co-founder of XENOTHERA.
*****************
About XENOTHERA:
Founded in 2014, XENOTHERA is a Nantes-based biotech that develops new therapeutic modes in many fields (immunology, oncology, viral infections...). The company develops treatments based on a unique proprietary technology of "glyco-humanized polyclonal antibodies (GH-pAb)”. Its technological platform is built on a dual expertise in genetics and immunology.
The biotech has a complete portfolio of products, including three products in clinic: LIS1, an immunosuppressant for solid organ transplantation; XAV-19, an anti-Covid treatment for patients with moderate disease; and XAB05, for the prevention and treatment of multi-drug resistant bacterial infections.
XENOTHERA, is part of the scientific and medical environment of the Pays de la Loire (France). The company has raised 43M€ since its creation, its main investors are the Pays de la Loire Region, BPI France and the European EIC Fund.
More information: www.xenothera.com
Follow XENOTHERA on social networks: LinkedIn Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230105005061/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom